US Edition
Published • loading... • Updated
Latigo Biotherapeutics Appoints Sara M. Bonstein to its Board of Directors and as Audit Committee Chair
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Latigo Biotherapeutics Appoints Sara M. Bonstein to its Board of Directors and as Audit Committee Chair
Experienced chief financial officer brings deep financial and strategic leadership to Latigo’s board of directors Appointment supports continued operational growthTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the appointment of Sara M. Bonstein as an independent director on the Company’s board …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
